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Hemolysis results in the release of hemoglobin and heme into the bloodstream and is associated with the development
of several pathologic conditions of different etiology, including hemoglobinopathies, hemolytic anemias, bacterial infections,
malaria, and trauma. In addition, hemolysis is associated with surgical procedures, hemodialysis, blood transfusion, and other
conditions in which mechanical forces can lead to red blood cell rupture. Free plasma hemoglobin and heme are toxic for the
vascular endothelium since heme iron promotes oxidative stress that causes endothelial activation responsible for vasoocclusive
events and thrombus formation. Moreover, free hemoglobin scavenges nitric oxide, reducing its bioavailability, and heme
favours ROS production, thus causing oxidative nitric oxide consumption. This results in the dysregulation of the endothelium
vasodilator:vasoconstrictor balance, leading to severe vasoconstriction and hypertension. Thus, endothelial dysfunction and
impairment of cardiovascular function represent a common feature of pathologic conditions associated with hemolysis. In this
review, we discuss howhemoglobin/heme released following hemolysismay affect vascular function and summarise the therapeutic
approaches available to limit hemolysis-driven endothelial dysfunction. Particular emphasis is put on recent data showing the
beneficial effects obtained through the use of the plasma heme scavenger hemopexin in counteracting heme-mediated endothelial
damage in mouse models of hemolytic diseases.
1. Hemolytic Diseases
Hemolysis is a pathologic condition characterized by the
increased release of hemoglobin (Hb) and heme. Several
human diseases and pathologic situations with different
etiology are associated with hemolysis including paroxysmal
nocturnal hemoglobinuria (PNH), sickle-cell disease (SCD),
thalassemias, hereditary spherocytosis and stomatocytosis,
microangiopathic hemolytic anemias, pyruvate kinase defi-
ciency, ABOmismatch transfusion reaction, paroxysmal cold
hemoglobinuria, severe idiopathic autoimmune hemolytic
anemia, infection-induced anemia, and malaria [1, 2]. More-
over, several recent studies indicate that hemolysis is also
associated with procedures including hemodialysis, blood
transfusion, and cardiac bypass inwhichmechanical shearing
forces may lead to red blood cell rupture [3].
During hemolysis, red blood cells release Hb, which form
stable complexes with the acute phase protein haptoglobin
(Hp) [4]. The Hp-Hb complexes are cleared from circulation
by monocytes and macrophages expressing the scavenger
CD163 receptor. The function carried out by Hp is crucial,
as demonstrated by studies on animal models and humans
(recently reviewed in Schaer et al. [5]). When Hp’s buffering
capacity is overwhelmed, Hb undergoes a rapid conversion
to metHb, liberating heme. Ferriheme then binds to albumin
and other plasma components including lipoproteins and is
subsequently transferred to hemopexin (Hx) [6, 7]. Hp and
Hx, by binding with high affinity Hb and heme, respectively,
block their prooxidant effects [4, 8]. Heme that escapes the
binding to Hx enters into cells and is neutralized by heme
oxygenases (HO). HO degrades the heme ring into iron,
carbonmonoxide (CO), and biliverdin, thus exerting primary
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anti-inflammatory, antioxidant, and antiapoptotic effects [2,
9–11]. In mammals, biliverdin is then rapidly converted into
bilirubin by biliverdin reductase and excreted into the bile
[12]. To date, three isoforms of HO have been identified,
HO-1, HO-2, and HO-3, encoded by three different genes.
The expression, distribution, and regulation, of HO-1, HO-
2 and HO-3 differ among cell types and tissues. HO-3 has
poor heme degrading capacity [13] and is now considered a
pseudogene, whereas HO-1 and HO-2 are the actual heme-
degrading enzymes [14]. HO-1 levels have been demon-
strated to be low under normal physiological conditions
but highly inducible by several stimuli including heme and
other oxidant agents, while HO-2 has been described as a
constitutively expressed enzyme [2, 15, 16]. The activity of
HO is strictly associated with the function of ferritins and
cytosolic proteins that sequester iron coming from heme
catabolism. Ferritins are composed of varying ratios of two
different subunits: H-ferritin and L-ferritin. H-ferritin is
endowed with a ferroxidase activity and is essential for iron
incorporation into the core of large L-ferritin and H-ferritin
complexes [17].
In hemolytic diseases, cell-free plasmaHbandhemeover-
whelm homeostatic systems in place to remove them. As a
consequence, various hemolytic diseases of different etiology
share hemoglobinemia-related sequelae, characterized by
endothelial dysfunction, thrombosis, vascular disease, and
renal failure [14]. Observations from the clinical adminis-
tration of artificial, purified, and recombinant Hb solutions
have provided support for the causal relationship between
excess cell-free Hb/heme in the bloodstream, symptoms, and
cardiovascular events. In particular, pulmonary hypertension
(PH) is emerging as one of the leading causes of morbidity
and mortality in patients with hemolytic anemias, including
SCD, thalassemia, PNH, hereditary spherocytosis and stom-
atocytosis, microangiopathic hemolytic anemias, pyruvate
kinase deficiency, and possibly malaria [18–26].
In the last decades, medical advances in the man-
agement of patients suffering from SCD, thalassemia and
other hemolytic anemias have led to significant increase in
life expectancy [27]. Improved public health with neonatal
genetic screening, parental and patient education, advances
in red cell transfusion medicine safety, aggressive iron chela-
tion therapy, penicillin prophylaxis for children under 6
years of age, immunization, and hydroxyurea therapy has all
likely contributed to this effect on longevity [28]. Now, as a
generation of patients with SCD and thalassemia ages, new
chronic vascular complications of these hemoglobinopathies
develop.
Here, we first discuss the causal relationship between
hemolysis and endothelial dysfunction, and then we focus
on different therapeutic approaches aimed at counteracting
hemolysis-driven adverse effects on the vasculature.
2. Hemolysis and Endothelial Dysfunction
Chronic intravascular hemolysis is associated with proox-
idant and proinflammatory stresses and with a state of
endothelial dysfunction characterized by reduced nitric oxide
(NO) bioavailability [29–31] and coagulopathy [32], leading
to vasomotor instability and ultimately to vasculopathy [33].
The causal link between endothelial dysfunction and hemoly-
sis has been well documented. Endothelial dysfunction is the
earliest clinically detectable stage of cardiovascular disease
characterized by a shift of the actions of the endothelium
toward reduced vasodilation, a proinflammatory state, and
prothrombotic properties [29, 34–37].
The entire circulatory tree is lined by a single epithelial-
like layer of vascular endothelial cells (ECs). Although ECs
exhibit characteristics that vary with anatomic location, both
by organ system and by vessel type (e.g., artery, arteriole,
capillary, venule, and vein), all ECs share common features
that distinguish them from other cell types and allow them
to perform critical homeostatic functions. Key homeostatic
functions include retaining blood fluid, regulating blood flow,
regulating macromolecule and fluid exchange with the tis-
sues, preventing leukocyte activation, and aiding in immune
surveillance for pathogens [38]. Injury or cell death impairs or
prevents conduct of these activities, resulting in dysfunction.
Most endothelial cell death is apoptotic, involving activation
of caspases [39, 40].
Stimuli that can cause endothelial injury or death include
oxidative stress, endoplasmic reticulum stress, metabolic
stress, and genotoxic stress, as well as pathways of injury me-
diated by the innate and adaptive immune systems [41]. He-
molysis is directly involved in endothelial injury, and recent
data suggest that chronic intravascular hemolysis is associ-
ated with a state of endothelial dysfunction, leading to hyper-
tension [29, 30, 42, 43]. Some of these vascular effects, pre-
disposing to hemolysis-associated hypertension, are linked to
cytotoxic, proinflammatory, and prooxidant effects of iron-
containing Hb and heme, whereas others are related to NO
scavenging by excess plasma Hb [18, 44].
2.1. Hemolysis-Driven Oxidative Stress and Endothelial Acti-
vation. Because of chronic hemolysis, hemolytic patients
are exposed to reactive oxygen species (ROS) generation
catalyzed by heme-derived redox-active iron, the vessel wall
being the primary exposed tissue. In the last years, it has
been demonstrated that oxidative stress and inflammation
directly contribute to vasoocclusive events and thrombus
formation in hemolytic patients. Belcher and coauthors
proposed that Hb, heme, and iron derived from hemolytic
red blood cells promote excessive ROS production, leading
to endothelial activation and adhesion molecule expression
on the vessel wall, which in turn favour the adhesion of red
blood cells and leukocytes to the endothelium, thus resulting
in vascular instability and eventually vasoocclusion [42, 43].
Intravital microscopy studies on SCD mice demonstrated
the critical role of adhesion molecules, such as P-selectin,
VCAM-1, and ICAM-1, for the interaction of sickle red blood
cells and leukocytes with the vessel wall and that blockade
or knockout of these molecules prevents either cytokine-
or hypoxia-induced stasis. In 𝛽-thalassemia, studies have
reported increased levels of vascular adhesion molecules,
indicating that endothelial dysfunction participates in throm-
botic events.
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2.2. Hemolysis-Mediated NO Bioavailability Reduction. In
hemolytic patients, hemolysis-driven endothelial dysfunc-
tion is characterized by reduced NO bioavailability and NO
resistance. This leads to dysregulation of the endothelium-
derived vasodilator:vasoconstrictor system, thus causing
severe vasoconstriction [19, 33, 45, 46].
NO is a potent endogenous vasodilator produced in en-
dothelium by the endothelial NO synthase (NOS) enzyme,
thanks to the oxygen-dependent conversion of L-arginine to
citrulline. Once produced, NO can diffuse from the endo-
thelium to adjacent smooth muscle where it binds avidly
to the heme moiety of soluble guanylate cyclase. This acti-
vates the enzyme, which in turn converts GTP to cGMP,
activating cGMP-dependent protein kinases and producing
vasodilation. In addition to this vasodilation,which is tonic in
nature and controls approximately 25% of our resting blood
flow, NO promotes general vascular homeostasis and health
[47]. NO tonically downregulates transcription of endothelial
adhesion molecule genes, such as VCAM-1, ICAM-1, P-
selectin, and E-selectin [48]. Nitric oxide also inhibits platelet
activation, tissue factor expression, and thrombin generation
[49]. NO modulates the expression of endothelin receptors
(promoting a vasodilator effect by increase in endothelial-
endothelin receptor B expression) and decreases expression
of endothelin 1, a potent mitogen and vasoconstrictor [50].
It is now well accepted that during hemolysis, cell-free
oxyHb in the plasma functions as an NO scavenger, produc-
ing metHb and nitrate (NO3−) in a reaction that is fast and
irreversible [5]. Normally, in the absence of hemolysis, the
amount of NO scavenged by Hb is greatly limited by the Hb
sequestration within the red blood cell plasma membrane.
This sequestration produces major bulk diffusional barriers
to NO, which include an unstirred layer around the red
blood cell, an intrinsic membrane permeability barrier to
NO, and a cell-free zone along the endothelium in laminar
flowing blood. These combined barriers reduce the reaction
rate of NO with intracellular Hb by approximately 1000-
fold [51]. In hemolytic disorders, the diffusional barriers
created by the red cell membrane that limits NO reactions
with Hb are disrupted, and the cell-free plasma Hb destroys
NO at a rate of 1000-fold faster than intraerythrocytic Hb,
resulting in abnormally high rates ofNOconsumption, which
produces a state of resistance to NO activity [37, 46, 51,
52]. Consequently, smooth muscle guanylyl cyclase is not
activated, and vasodilation is impaired. In support of this
mechanism, plasma from patients with SCD contains oxyHb,
which reacts with and consumes micromolar quantities of
NO and inhibits forearm blood flow responses to NO donor
infusions [34]. Remarkably, kinetic models suggest that levels
of plasma Hb as low as 1 𝜇M have the potential to impair
endothelial NO signaling, and heme concentrations as low as
6 𝜇Mhave been found to impair NO-dependant vasodilation
in vivo in SCD patients [34]. Similar effects of hemolysis
on NO bioavailability and endothelial function have recently
been reported in malaria [53].
In hemolytic disorders, consumption/inactivation of NO
is accelerated due not only to Hb scavenging but even to
chronic oxidative stress promoted by free heme. In these
patients, heme-induced ROS production is implicated in NO
consumption and formation of peroxynitrite and in NOS
uncoupling [18, 54]. Finally, hemolysis also releases arginase-
1 from red blood cells that react with NOS substrate, L-
arginine, to form ornithine, effectively reducing L-arginine
availability for NO production by endothelial NOS. This
results in a perpetual activation of the vascular endothelium
because of chronic oxidative stress, hemolysis, and reduced
NO [55].
2.3. Hemolysis-Induced Thrombosis. In addition to the toxic
effects above reported, excessive plasma Hb and heme may
contribute to platelet activation and thrombosis. The infu-
sion of cross-linked Hb increases platelet aggregation and
adhesion in vivo on prothrombotic surfaces such as an
injured vessel wall. Administration of heme in healthy volun-
teers is associated with thrombophlebitis, demonstrating that
heme can cause vascular inflammation followed by vascular
obstruction in vivo [56, 57]. Interestingly, the addition of cell-
free Hb to human serum at concentrations of 0.2 to 2.0 g/dL
causes a dose-dependent inhibition of the metalloprotease
ADAMTS13, an enzyme critical in limiting platelet thrombus
formation. The major untoward effects of plasma Hb and
heme on platelet function are most likely mediated by the
scavenging ofNO.NO interactswith components of the coag-
ulation cascade to downregulate clot formation. In particular,
NO has been shown to inhibit platelet aggregation, induce
disaggregation of aggregated platelets, and inhibit platelet
adhesion through increasing cGMP levels [58]. In fact, NO
donor drugs (S-nitrothiols) that increase systemic levels of
NO have been shown to inhibit platelet aggregation [59].
Conversely, NO scavenging by Hb or the reduction of NO
generation by the inhibition of arginine metabolism results
in an increase in platelet aggregation [34]. In animal models,
reduction of NO causes increases in fibrin split products
and thrombin-antithrombin complexes leading to significant
fibrin deposition and thrombus formation. Moreover, in a
patient with L-arginine deficiency, reduced NO production is
associated with increased thrombin-antithrombin complexes
and fibrin split products, while reversal of NOdeficiencywith
L-arginine causes a reduction in intravascular coagulopathy
[33, 35, 60, 61].
The adverse effects of hemolysis on the vasculature are
summarized in Figure 1.
In the next two sections, we report the “state of the art” on
themolecules used to limitHb/heme toxicity on endothelium
and then discuss our recent data on the therapeutic use of the
plasma heme scavenger Hx.
3. Use of Therapeutic Molecules to Counteract
Hb/Heme-Driven Endothelial Dysfunction
As stated above, the critical roles of endothelial activation,
inflammation, and oxidative stress in the pathophysiology of
hemolytic diseases have been well established. These studies
open the possibility that the administration of antioxidants,
inhibitors of endothelial activation, or agents able to restore
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Figure 1: Hemolysis-driven endothelial toxicity. Free Hb/heme is responsible for reducedNO availability and ROS generation that contribute
to endothelial dysfunction leading to vasoconstriction, hypertension, and vasoocclusion. See text for details.
NO homeostasis, could positively affect cardiovascular func-
tion in hemolytic diseases. Moreover, promising therapies
are based on systems aimed at enhancing heme degradation
and at scavenging Hb/heme from circulation. Several clinical
trials testing the effect of such molecules are ongoing.
3.1. Antioxidants. Theantioxidant niacinwas found to inhibit
vascular inflammation by decreasing endothelial ROS pro-
duction and subsequent LDL oxidation and inflammatory
cytokine production, key events involved in atherogene-
sis, highlighting vascular anti-inflammatory and potentially
antiatherosclerotic properties for this molecule. Treatment
with niacin was observed to improve endothelial dysfunction
in patients with coronary artery disease and low high-density
lipoproteins cholesterol. Niacin is expected to similarly act
in SCD, causing an improvement in blood flow, and clinical
trials are currently evaluating its therapeutical potential [62].
It has recently been demonstrated that niacin induces HO-1
and that the inhibition of HO activity attenuates the ability of
niacin to inhibit vascular inflammation [63]. These data sug-
gest that the protective effect of niacin on vascular function
could be mediated by HO-1 and its products. Nevertheless,
it should be taken into account that niacin/nicotinic acid is
mildly hemolytic at pharmacologic doses [64], and therefore,
it could exacerbate hemolytic damage thus rendering its use
not so effective for the treatment of hemolytic patients.
The effect of the supplementation of another molecule,
glutamine, in hemolytic patients is under evaluation [65,
66]. Glutamine is expected to improve the erythrocyte
glutamine/glutamate ratio, a biomarker of oxidative stress,
hemolysis, and PH in SCD and thalassemia patients and
increase arginine bioavailability and subsequently alter sickle
red cell endothelial interaction and clinical outcome [65, 67].
Additionally, oral glutamine is supposed to decrease bio-
markers of hemolysis and adhesion molecules and improve
the imbalanced arginine-to-ornithine ratio that occurs in
hemolytic anemias, leading to improved arginine bioavail-
ability and clinical endpoints of endothelial dysfunction and
PH in patients with SCD and thalassemia [65, 66].
The protective effect of erythritol against endothelial dys-
function is also currently being tested. Erythritol, by inducing
the expression of SOD2, activates the cell’s own antioxidant
machinery [68]. This activation or upregulation provides a
protective effect to the endothelium and prevents endothelial
dysfunction and hemolysis in the streptozotocin diabetic rat
[68]. Thus, erythritol could be utilized to treat or prevent
hypertension [68].
3.2. Adhesion Molecules Inhibitors. Recent studies suggest a
beneficial effect for adhesion molecule inhibitors against he-
molysis-induced vasculopathy. Among these molecules, the
HDAC inhibitor trichostatin A and its analog suberoylanilide
hydroxamic acid were found to markedly reduce endothelial
activation and tissue factor expression in transgenic sickle
mice, thus preventing vascular stasis [69].
Similarly, the small-molecule cyclic 𝛼V𝛽3 and an anti-P-
selectin aptamer decrease the adhesion of sickle red blood
cells and leukocytes to endothelial cells in mouse model of
Oxidative Medicine and Cellular Longevity 5
SCD, suggesting a potential use of these molecules as novel
therapeutic agents for vasculopathy associated with hemo-
lytic pathologies [70, 71].
3.3. Agents Aimed at Restoring NOHomeostasis. In hemolytic
patients, hemolysis-driven endothelial dysfunction is char-
acterized by reduced NO bioavailability and NO resistance,
leading to severe vasoconstriction. The effects of cell-free
plasma Hb on NO consumption have been shown in clinical
trials of Hb-based blood substitutes, in which various cell-
free Hb preparations given to humans and animals showed
dose-dependent effects on vasoconstriction, PH, and sys-
temic hypertension. Induced intravascular hemolysis in a dog
model promoted NO consumption and subsequent vasocon-
striction and renal dysfunction [72]. This phenomenon has
also been noted in patients with SCD. In these studies, the
vasoconstrictive effects of NO depletion caused by hemolysis
could be counteracted by inhaled NO, which reacts directly
with the cell-free Hb in the pulmonary circulation, oxidizing
it tometHb, which cannot then scavenge theNO systemically
[73].
Additional studies provide evidence for a beneficial effect
of inhaled NO and S-nitrosoalbumin on pulmonary injury
induced by hypoxia/reoxygenation in a mouse model of
SCD [74]. These observations provide new insights into the
possible use of NO donors in the treatment of acute lung
injury and vasoocclusive crisis in SCD.
A role for arginine supplementation as a novel NO-
based therapy for SCD has been proposed [75]. Argi-
nine therapy increases NO bioavailability, thus resulting in
improved microvascular function and reduced oxidative
stress [75]. Consequently, arginine administration decreases
pulmonary pressures in patients with SCD and secondary PH
and inhibits endothelin-1-mediated activation of the Gardos
channel in transgenic SCD mice, thus limiting erythrocyte
dehydration and hemolysis [54, 76, 77].
Another development in our understanding of Hb-NO
biology is the appreciation that Hb possesses a nitrite reduc-
tase and anhydrase activity that can convert nitrite to NO
and N
2
O
3
, respectively, offsetting the Hb-dependent NO
scavenging by vasodilation. Nitrite reacts with deoxygenated
Hb to form metHb and NO. Consistent with this theory,
recent studies have examined the addition of nitrite to Hb-
based oxygen carriers and found that low concentrations of
nitrite reverse the vasoconstrictive effects. According to
this hypothesis, low doses of nitrite could be given before
hemodialysis, cardiopulmonary bypass, or transfusion of
aged blood to limit the cardiovascular toxicity of NO scav-
enging [78].
3.4. Enhanced Heme Degradation. In hemolytic patients, he-
me that accumulated in endothelial cells and in tissues is
degraded byHO,mainly by the inducible HO-1 enzyme. HO-
1 by exerting anti-inflammatory, antiproliferative, antiapop-
totic, and antioxidant effects on the vasculature has been
shown to protect against atherosclerosis [79]. Moreover, it
promotes vascular repair after injury and prevents chronic
allograft deterioration in heart transplantation [80, 81].
HO-1 protective effects are mediated by the products of
heme catabolism, CO that is a strong vasodilator, and
biliverdin/bilirubin that has antioxidant properties and can
regulate the expression of protective genes [2]. In particular,
biliverdin/bilirubin themselves scavenges multiple oxidants
including superoxide, whichwould decreaseNObioavailabil-
ity, induce peroxynitrite formation and contribute to dysreg-
ulation of endothelial function [82, 83]. SCD patients and
mice showed an adaptive upregulation ofHO-1 in response to
hemolysis, and several data demonstrated the cardiovascular
protective function of HO-1 [43, 84, 85]. Belcher and coau-
thors demonstrated that treatment of sickle mice with hemin
to increase HO-1 expression inhibits hypoxia/reoxygenation-
induced stasis, leukocyte-endothelium interactions, and NF-
kappaB, VCAM-1, and ICAM-1 expressions. On the other
hand, HO inhibition exacerbates stasis in sickle mice. Fur-
thermore, treatment of sickle mice with the HO enzymatic
product CO or biliverdin inhibits stasis and NF-kappaB,
VCAM-1, and ICAM-1 expressions [43]. Another promising
approach is based on the use of viral vectors or transposases
to increase HO-1 expression [84, 86].
3.5. Plasma Hb Scavenging. Several studies reported the
beneficial effects of Hp on inhibiting Hb toxicity [5, 72, 87]. A
recent study published by Boretti et al. reports that cell-free
plasmaHb has potent oxidative properties that are associated
with hypertensive effects. They also found that increasing
the levels of Hp in the circulation reduced this oxidative
stress and limited both the hypertensive effects and the renal
insufficiency associated with plasma hemoglobinemia [72].
Other studies reported the therapeutic use of Hp in ani-
mal models of transfusion-associated hemolysis [88]. Finally,
Hp has already been used in several clinical trials in Japan.
The therapeutic use of Hp has been extensively reviewed
by [5].
The different therapeutic approaches discussed in this
section are illustrated in Figure 2.
4. The Plasma Heme Scavenger Hemopexin
Hx is a glycoprotein mainly produced by the liver and re-
leased into plasma (plasma concentration: 0.5–1mg/mL in
humans and rodents) where it binds heme with very high
affinity. Other than the liver, other sites of Hx synthesis are
kidney mesangial cells, neurons, and glial cells of the central
nervous system, Schwann cells, and ganglionic and photore-
ceptor cells of the retina and skeletal muscle [4, 89, 90]. Hx
structure is characterized by two domains, resembling two
thick disks that lock together at a 90∘ angle, joined by a linker
peptide.The structure of Hx is characterized by its conserved
clustering of histidine residues present in His-Gly sequences
that coordinate heme [91].The heme ligand is bound between
the two domains ofHx in a pocket formed by the interdomain
linker peptide. Heme binding and release result fromopening
and closing of the heme-binding pocket, through movement
of the two domains and/or interdomain linker peptide [92].
Plasma level of Hx rises during the acute phase response
following inflammation and heme overload [93]. Hx syn-
thesis is mainly controlled at the transcriptional level. The
human Hx promoter contains a specific cis-acting element,
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Figure 2: Therapeutic approaches aimed at counteracting Hb/heme toxicity. It is possible to use agents to restore NO availability, to limit
ROS production and inflammation, to induce the protective HO-1 gene, to use Hb/heme scavengers to block Hb/heme adverse effects, or to
chelate heme-derived prooxidant iron. In principle, combined therapies, by acting at different levels, could be even more effective.
called Hpx A site, which is responsible for interleukin-6-
mediated induction of Hx expression [94–96]. On the other
hand, it is unknown whether heme directly controls Hx
expression [4].
Studies in Hx-null mice demonstrated a crucial role for
this protein in the protection against hemolytic damage. Hx-
null mice are highly sensitive to phenylhydrazine-induced
intravascular hemolysis and to heme overload obtained
through intravenous injection of heme [8, 97, 98]. The Hx
protective effect is particularly evident on the vasculature,
the liver, and the kidney [8]. After heme overload, vessels
of Hx-null mice showed an increased induction of adhesion
molecules and suffered from oxidative stress. Moreover, NO
availability after heme overload was reduced in Hx-null
mice, and this was likely due to NOS uncoupling subse-
quent to heme-promoted ROS generation. Vessel damage
was particularly evident in the liver of heme-overloaded Hx
knockout mice, where sinusoids appeared congested. Finally,
proinflammatory cytokines expression was increased in Hx-
null mice after heme overload indicating that Hx can very
efficiently limit heme inflammatory effects [8, 99].
Recently, we demonstrated that the Hx protective effect
on the endothelium was achieved through the prevention of
heme entry into endothelial cells (and/or heme intercalation
in endothelial cell membranes) and the promotion of heme
detoxification by the liver [99]. Hx very efficiently promotes
heme uptake by hepatocytes that detoxify it through HO and
direct excretion in the bile. This in vivo study confirms the
previously reported in vitro results showing that treatment
of hepatoma cell lines with heme-Hx complexes resulted in
the induction of HO-1 and ferritins and thus in an efficient
heme catabolism. Moreover, we were able to demonstrate
that heme enters into endothelial cells if bound to albumin,
but not if bound to Hx, and this was associated with the
protection against heme-induced oxidative stress and to the
prevention of adhesion molecules induction [99]. Similar
results were obtained on macrophages as Hx also prevents
heme entry into this cell type and macrophage activation
(Vinchi et al., unpublished data). Interestingly, it has been
reported that apo-Hx blocks the induction of IL-6 and TNF𝛼
in LPS-treated macrophages [100, 101]. This suggests that Hx
can have an anti-inflammatory function independent from its
heme scavenger function, likely by acting on TLR4-activated
pathways.
5. Therapeutical Use of Hx to Limit
Heme-Driven Endothelial Dysfunction in
Hemolytic Disorders
We recently showed the effects of an Hx-based therapy in
mouse models of two hemolytic disorders, SCD and 𝛽-
thalassemia. Both these diseases, despite having different
etiology and clinical settings, have high rate of intravascular
hemolysis as a common feature. Both of these disorders can
cause fatigue, jaundice, and episodes of pain ranging from
mild to severe. Dysfunction of the liver, lung, kidney, and
heart is common, and stroke may occur. Moreover, in severe
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forms of SCD and 𝛽-thalassemia, a transfusion regimen is
necessary, and this further exacerbatesHb/heme toxicity [33].
Our data show that Hx infusion alleviates heme-induced
endothelial activation, inflammation, and oxidative injury in
mouse models, thus suggesting important implication for a
therapeutic use of Hx in the treatment of hemolytic diseases
(Figure 2).
Hx treatment resulted in a marked improvement of the
health status of anemic mice and preservation of their organ
functionality. In particular, we demonstrated that Hx admin-
istration, by scavenging free heme, alleviates heme-induced
ROS formation and tissue oxidative injury and limits the
induction of adhesion molecules in SCD and 𝛽-thalassemia
mice, thus indicating that Hx may confer protection against
heme-driven oxidative stress as well as endothelial activa-
tion and inflammation [99]. Moreover, we showed that Hx
therapy promotes NOproduction by reducing heme-induced
oxidative consumption of NOS cofactors and NOS enzyme
uncoupling. Increased bioavailability of NO suggests that Hx
is able to positively affect vascular homeostasis, counteracting
endothelial dysfunction associated with hemolytic patholo-
gies [99].
Our recent data also indicate a strong antihypertensive
role for Hx in hemolytic pathologies. Hx therapy strongly
reduces blood pressure in hemolytic animals, counteracting
heme-induced vasoconstriction.This is further supported by
a marked decrease in cardiac output and aortic valve peak
pressure observed in SCD mice following Hx therapy [99].
Additionally, Hx administration reduces proinflamma-
tory cytokine production in hemolytic animals, supporting
a strong anti-inflammatory role for this molecule [99]. Com-
pared to other anti-inflammatory agents such as glucocorti-
costeroids that have a limited use in clinics because of their
side effects and immunosuppressive impact, Hx, by acting as
a physiologic heme chelator, is expected to be well tolerated.
We did not observe deleterious effects of the Hx therapy on
renal function in mice despite the fact that previous papers
had described a protease activity of serum Hx responsible
for proteinuria and glomerular alterations characteristic for
minimal change nephrotic syndrome in the rat [102, 103].This
might be due to the different preparations ofHx used or,more
likely, to the different pathologic models analysed. Our data
support the conclusion that Hx is the most important heme
scavenger under conditions of enhanced hemolysis as those
experienced by SCD and thalassemic mice when plasma
hemoglobin levels exceed haptoglobin binding capacity.
Hx exerts its protective effect mainly by enhancing HO
expression and activity in the liver and by limiting HO-1
induction in vascular endothelium and likely in other extra-
hepatic tissues [99].
In SCD and thalassemic patients, excess iron deposition
in the liver, further worsened by transfusion,may cause fibro-
sis/cirrhosis and hepatocellular carcinoma. Nevertheless, the
beneficial effects due to Hx treatment observed in anemic
mice support the idea that the organism can tolerate a greater
iron burden in the liver that is a tissue predisposed to iron
storage, while it is preferable to alleviate iron loading in
tissues, such as the heart and kidney that are not usually
predisposed to iron accumulation [104]. In addition, we
demonstrated that Hx treatment also promotes heme excre-
tion in the bile, thus providing a way for iron to directly leave
the body [99]. This represents a mechanism on which to act
in the future in order to enhance the liver heme detoxifying
potential.
On the other hand, by redirecting heme to the liver, Hx
limits heme uptake and prevents HO-1 induction as well as
iron loading and activation of endothelial cells, thus reducing
ROS production, inflammation, and, eventually, cell death.
These results are in agreement with data showing that HO-
1 transgene expression in the liver of sickle mice resulted in a
decrease in markers of vascular inflammation and inhibition
of vasoocclusion [84]. Indeed, an important outcome of Hx
therapy is the prevention of iron accumulation in the vascular
endothelium and in the heart. This has clinical relevance
since hemolysis-driven iron overload, exacerbated by blood
transfusions, strongly contributes to heart failure, one of the
most common causes of death in thalassemia patients. Our
results suggest that Hx administration could be beneficial in
transfused patients to alleviate the myocardial iron burden.
These data provide the rationale for the use of purified
or recombinant Hx and/or for the design of Hx-based drugs,
with high affinity for heme and rapidly cleared by the liver,
which might be used pharmacologically as heme chelators to
prevent heme-mediated tissue damage in patients suffering
from hemolytic diseases.
6. Conclusions
Free Hb/heme resulting from hemolysis is responsible for
reduced NO availability, oxidative stress, and inflamma-
tion, all contributing to vascular dysfunction. Therapeutic
approaches are aimed at enhancing heme degradation, at
counteracting heme prooxidant activity, at limiting endothe-
lial activation, and at preserving NO homeostasis. Promising
novel therapies are based on the use of plasma Hb and heme
scavengers to prevent Hb/heme toxicity. In particular, the use
of purified Hx in mouse models of SCD and 𝛽-thalassemia
has provided the proof of principle of such approach. Future
studies are needed to translate these results into clinical
practice. Considering that the different approaches described
in this review target different levels of the cascade of events
starting with Hb/heme overload and ending with vascular
dysfunction, it is time to speculate on the effectiveness of
combined therapies. For instance, we expect that promoting
Hb and heme scavenging with Hp and Hx, respectively,
and simultaneously enhancing HO-1 expression may almost
completely avoid heme accumulation and consequently its
toxic effects. Similarly, the association of antioxidants and/or
drugs aimed at restoring NO may improve the effectiveness
of Hb/heme scavenging.
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